Literature DB >> 12507744

Family history validation of the bipolar nature of depressive mixed states.

Hagop S Akiskal1, Franco Benazzi.   

Abstract

BACKGROUND: Recent data indicate that depressive mixed states (DMX), major depressive episode (MDE) plus few concurrent hypomanic symptoms are common in clinical practice but omitted in DSM-IV. Our aims were to find the sensitivity and specificity of DMX for the diagnosis of bipolar II disorder, and validate it against familial bipolarity.
METHODS: 377 consecutive private outpatients presenting with psychoactive drug-free MDE were interviewed with the Structured Clinical Interview for DSM-IV (Clinician Version). History of past hypomanic episodes and presence of hypomanic symptoms during the index MDE were systematically recorded. Of these, 226 were bipolar II and 151 unipolar. DMX3 was defined as an MDE plus three or more intra-episodic hypomanic symptoms.
RESULTS: DMX3 was present in 58.4% of bipolar II, and 23.1% of unipolar patients. It was significantly associated with variables distinguishing bipolar from strictly defined unipolar disorders (younger age at onset, more MDE recurrence, more atypical features, more bipolar II family history). Unipolar DMX3 (MDE with documented hypomania solely intra-episodically) was not significantly different from bipolar II MDE on age at onset, atypical features, and bipolar II family history.
CONCLUSIONS: Results support the inclusion of DMX3 (bipolar II and 'unipolar') into the bipolar spectrum. Adding the 23% of the UP-DMX3 to the roster of less-than-manic outpatient depressives will boost the rate of bipolarity in this outpatient depressive population to a respectable 70%, the highest rate yet reported for the bipolar spectrum below the threshold of mania.

Entities:  

Mesh:

Year:  2003        PMID: 12507744     DOI: 10.1016/s0165-0327(02)00330-0

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  19 in total

1.  Gender differences in bipolar-II disorder.

Authors:  Franco Benazzi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-05       Impact factor: 5.270

Review 2.  Relationship of anger and anger attacks with depression: a brief review.

Authors:  Nitesh Painuly; Pratap Sharan; Surendra K Mattoo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

3.  Testing atypical depression definitions.

Authors:  Franco Benazzi
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

4.  The continuum/spectrum concept of mood disorders: is mixed depression the basic link?

Authors:  Franco Benazzi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-09-07       Impact factor: 5.270

Review 5.  Subthreshold bipolarity: diagnostic issues and challenges.

Authors:  Robin Nusslock; Ellen Frank
Journal:  Bipolar Disord       Date:  2011 Nov-Dec       Impact factor: 6.744

Review 6.  The significance of mixed states in depression and mania.

Authors:  Giulio Perugi; Giuseppe Quaranta; Liliana Dell'Osso
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

7.  Manic symptoms and impulsivity during bipolar depressive episodes.

Authors:  Alan C Swann; F Gerard Moeller; Joel L Steinberg; Laurie Schneider; Ernest S Barratt; Donald M Dougherty
Journal:  Bipolar Disord       Date:  2007-05       Impact factor: 6.744

8.  Continuum of depressive and manic mixed states in patients with bipolar disorder: quantitative measurement and clinical features.

Authors:  Alan C Swann; Joel L Steinberg; Marijn Lijffijt; Gerard F Moeller
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

9.  Toward better probing for hypomania of bipolar-II disorder by using Angst's checklist.

Authors:  Franco Benazzi
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

Review 10.  Bipolar II disorder : epidemiology, diagnosis and management.

Authors:  Franco Benazzi
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.